• Home
  • Our Technology
  • The Team
  • Collaborators
  • Contact Us

Collaborators

Partnering
Picture
Ducentis is working with world class contract research organizations in order to rapidly develop a portfolio of CD200 variant molecules with a data package supporting efficacy and safety in pre-clinical models.

Prosarix
​We are working with Prosarix on developing in silico models of CD200 variants and using these models to design CD200 variants with improved pharmacology and pharmaceutical properties. 
www.prosarix.com

Syngene
We are working with Syngene on characterisation of CD200 mutants in cell free assays.
www.syngeneintl.com

GVK Gio Accelerating Research
We are working with GVK on cloning, expression, purification and stability studies with CD200 mutants. 
www.gvkbio.com

Picture
​We are working with KWS to characterise CD200 variants in in vitro assays using primary human immune cells and rodent models of autoimmunity and inflammatory disease.
www.kwsbiotest.com
Partners
Picture
Ducentis is open to partnering the CD200 program with pharma or biotech companies seeking to invest in novel biologic therapies for autoimmune disease. 

Contact Us >

Ducentis

Our Technology  |  The Team  |  Collaborators

Connect

Contact Us

Legals

Disclaimer
​Ducentis BioTherapeutics Ltd is a company registered in England. 
Registered office address:
264 Banbury Road, Oxford, Oxfordshire, OX2 7DY
Company registration number: 9307415.
© Copyright Ducentis BioTherapeutics 2019   |   Website Design & Development by Creative Remedy
  • Home
  • Our Technology
  • The Team
  • Collaborators
  • Contact Us